Literature DB >> 20202149

Oral glucose tolerance testing in children with cystic fibrosis.

Katie Larson Ode1, Brigitte Frohnert, Theresa Laguna, James Phillips, Bonnie Holme, Warren Regelmann, William Thomas, Antoinette Moran.   

Abstract

BACKGROUND: Cystic fibrosis (CF) related diabetes is the most common comorbidity in persons with CF. International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines recommend annual oral glucose tolerance testing (OGTT) screening starting at age 10. The OGTT might be recommended in younger children if, as in adults, it provided clinically relevant prognostic information. A database review was performed to determine whether OGTT findings in children with CF predict subsequent clinical course.
METHODS: A retrospective matched-pair cohort study was based on OGTTs performed during 1998-2003. Children aged 6-9 were classified as having normal glucose tolerance (NGT) or abnormal glucose tolerance (AGT). Children with AGT were matched by age and gender to those with NGT. Clinical status was assessed at baseline and 5 yr later. In a separate investigation, diabetes and prior AGT status of children aged 10-18 were used to assess predictions derived from the cohort study.
RESULTS: In 1998-2003, 39 of 94 children had AGT. Of these, 31 had sufficient follow-up data to be included. Both at baseline and 5 yr later there was no significant difference in height, weight, body mass index (BMI) or lung function between AGT and NGT. Diabetes developed in 13 AGT (42%) and one NGT (3%) [odds ratio (OR) 11, p = 0.0009]. Age of diabetes onset was 12 ± 1 yr in boys and 11 ± 1 yr in girls, compared to approximately 23 yr in the general CF population. Fifteen current children age 10-18 who had AGT before age 10 have diabetes, close to the prediction of 19.
CONCLUSIONS: AGT in children with CF age 6-9 yr identifies those at high risk for progression to early onset diabetes.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20202149      PMCID: PMC3856892          DOI: 10.1111/j.1399-5448.2009.00632.x

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  26 in total

1.  Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus.

Authors:  S Nousia-Arvanitakis; A Galli-Tsinopoulou; M Karamouzis
Journal:  Acta Paediatr       Date:  2001-05       Impact factor: 2.299

2.  Effects of tolbutamide on growth and body composition of nondiabetic children with cystic fibrosis.

Authors:  W B Zipf; C L Kien; C A Horswill; K S McCoy; T O'Dorisio; B L Pinyerd
Journal:  Pediatr Res       Date:  1991-10       Impact factor: 3.756

3.  Diabetes mellitus associated with cystic fibrosis.

Authors:  S M Finkelstein; C L Wielinski; G R Elliott; W J Warwick; J Barbosa; S C Wu; D J Klein
Journal:  J Pediatr       Date:  1988-03       Impact factor: 4.406

4.  Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis.

Authors:  C Koch; M Rainisio; U Madessani; H K Harms; M E Hodson; G Mastella; S G McKenzie; J Navarro; B Strandvik
Journal:  Pediatr Pulmonol       Date:  2001-11

5.  Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy.

Authors:  M A Rolon; K Benali; A Munck; J Navarro; A Clement; N Tubiana-Rufi; P Czernichow; M Polak
Journal:  Acta Paediatr       Date:  2001-08       Impact factor: 2.299

6.  Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline.

Authors:  C E Milla; W J Warwick; A Moran
Journal:  Am J Respir Crit Care Med       Date:  2000-09       Impact factor: 21.405

7.  The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis.

Authors:  Paulus Ripa; Ian Robertson; David Cowley; Margaret Harris; I Brent Masters; Andrew M Cotterill
Journal:  Clin Endocrinol (Oxf)       Date:  2002-03       Impact factor: 3.478

8.  Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis.

Authors:  S Lanng; B Thorsteinsson; J Nerup; C Koch
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

9.  Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections.

Authors:  S Lanng; B Thorsteinsson; J Nerup; C Koch
Journal:  Acta Paediatr       Date:  1994-08       Impact factor: 2.299

10.  Diabetes as a determinant of mortality in cystic fibrosis.

Authors:  Parinya Chamnan; Brian S F Shine; Charles S Haworth; Diana Bilton; Amanda I Adler
Journal:  Diabetes Care       Date:  2009-11-16       Impact factor: 19.112

View more
  27 in total

1.  Hypoglycemia and Islet Dysfunction Following Oral Glucose Tolerance Testing in Pancreatic-Insufficient Cystic Fibrosis.

Authors:  Marissa J Kilberg; Clea Harris; Saba Sheikh; Darko Stefanovski; Marina Cuchel; Christina Kubrak; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

2.  Incretin dysfunction and hyperglycemia in cystic fibrosis: Role of acyl-ghrelin.

Authors:  Xingshen Sun; Yaling Yi; Bo Liang; Yu Yang; Nan He; Katie Larson Ode; Aliye Uc; Kai Wang; Katherine N Gibson-Corley; John F Engelhardt; Andrew W Norris
Journal:  J Cyst Fibros       Date:  2019-02-07       Impact factor: 5.482

3.  Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure.

Authors:  Rebecca L Hull; Ronald L Gibson; Sharon McNamara; Gail H Deutsch; Corinne L Fligner; Charles W Frevert; Bonnie W Ramsey; Srinath Sanda
Journal:  Diabetes Care       Date:  2018-02-01       Impact factor: 19.112

4.  Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia.

Authors:  Marissa J Kilberg; Saba Sheikh; Darko Stefanovski; Christina Kubrak; Diva D De Leon; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels; Andrea Kelly
Journal:  J Cyst Fibros       Date:  2019-08-08       Impact factor: 5.482

Review 5.  Survival in a bad neighborhood: pancreatic islets in cystic fibrosis.

Authors:  Andrew W Norris; Katie Larson Ode; Lina Merjaneh; Srinath Sanda; Yaling Yi; Xingshen Sun; John F Engelhardt; Rebecca L Hull
Journal:  J Endocrinol       Date:  2019-02-01       Impact factor: 4.286

6.  Impaired fasting glucose in cystic fibrosis.

Authors:  Brigitte I Frohnert; Katie Larson Ode; Antoinette Moran; Brandon M Nathan; Theresa Laguna; Bonnie Holme; William Thomas
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 7.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

8.  Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis.

Authors:  Yaling Yi; Andrew W Norris; Kai Wang; Xingshen Sun; Aliye Uc; Antoinette Moran; John F Engelhardt; Katie Larson Ode
Journal:  Am J Respir Crit Care Med       Date:  2016-10-15       Impact factor: 21.405

Review 9.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

10.  Abnormal glucose tolerance and the 50-gram glucose challenge test in Cystic fibrosis.

Authors:  Saba Sheikh; A Russell Localio; Andrea Kelly; Ronald C Rubenstein
Journal:  J Cyst Fibros       Date:  2020-01-21       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.